1. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity.
- Author
-
Boeszoermenyi, Andras, Bernaleau, Léa, Chen, Xudong, Kartnig, Felix, Xie, Min, Zhang, Haobo, Zhang, Sensen, Delacrétaz, Maeva, Koren, Anna, Hopp, Ann-Katrin, Dvorak, Vojtech, Kubicek, Stefan, Aletaha, Daniel, Yang, Maojun, Rebsamen, Manuele, Heinz, Leonhard X., and Superti-Furga, Giulio
- Subjects
ANTI-inflammatory agents ,SYSTEMIC lupus erythematosus ,ALLOSTERIC regulation ,AUTOIMMUNE diseases ,IMMUNE system ,PATTERN perception receptors - Abstract
Dysregulation of pathogen-recognition pathways of the innate immune system is associated with multiple autoimmune disorders. Due to the intricacies of the molecular network involved, the identification of pathway- and disease-specific therapeutics has been challenging. Using a phenotypic assay monitoring the degradation of the immune adapter TASL, we identify feeblin, a chemical entity which inhibits the nucleic acid-sensing TLR7/8 pathway activating IRF5 by disrupting the SLC15A4-TASL adapter module. A high-resolution cryo-EM structure of feeblin with SLC15A4 reveals that the inhibitor binds a lysosomal outward-open conformation incompatible with TASL binding on the cytoplasmic side, leading to degradation of TASL. This mechanism of action exploits a conformational switch and converts a target-binding event into proteostatic regulation of the effector protein TASL, interrupting the TLR7/8-IRF5 signaling pathway and preventing downstream proinflammatory responses. Considering that all components involved have been genetically associated with systemic lupus erythematosus and that feeblin blocks responses in disease-relevant human immune cells from patients, the study represents a proof-of-concept for the development of therapeutics against this disease. The authors identify feeblin, an inhibitory compound of the proinflammatory TLR7/8/9-IRF5 pathway with therapeutic potential, which acts by binding SLC15A4 via an allosteric mechanism mediating degradation of its signaling partner TASL. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF